Contact
Please use this form to send email to PR contact of this press release:
Momenta Resumes Patient Enrollment in the Necuparanib (MOM-M402-103) Phase 2 Study
TO:
Please use this form to send email to PR contact of this press release:
Momenta Resumes Patient Enrollment in the Necuparanib (MOM-M402-103) Phase 2 Study
TO: